Metabolon Signs Collaboration with Army Medical Research Institute
News Nov 12, 2007
Metabolon, Inc. has announced the signing of a contract supporting the US Army Medical Research Institute of Infectious Diseases (USAMRIID).
The collaboration uses Metabolon’s proprietary metabolomics platform to study the biochemical profiles of humans given the AVA anthrax vaccine. The AVA vaccine is the only FDA-licensed anthrax vaccine for humans.
“This collaboration represents the first large-scale metabolomics study of human subjects given a vaccine,” said Mike Milburn, Metabolon’s Chief Scientific Officer. “This type of comprehensive biochemical profiling will help USAMRIID better understand the vaccine’s safety, efficacy, and mechanism of action.”
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE